Aptyx, a global developer and manufacturer of complex components and devices for the life sciences, has acquired the Charlotte, North Carolina facility of Medical Murray, which develops and produces catheter-based interventional products and transcatheter implants.

This acquisition will become an integral part of Aptyx Interventional Systems, fortifying the company’s interventional and implantable expertise. It also expands the company’s ISO Class 7 footprint and brings expertise in biotextiles such as ePTFE covering stents and frames.

“This marks a significant step in our growth strategy, strengthening our interventional product capabilities and end-to-end offerings, driving innovation, and delivering greater value to our OEM life science customers,” said Gregg Tobin, President and CEO, Aptyx. “It is a key element of our original blueprint and just the beginning of our evolution, with much more growth to follow.”

Eric Leopold, who served as CTO of Medical Murray and leader of the Charlotte, NC business, will join Aptyx post-acquisition as Senior Vice President. Charlotte team members will become part of Aptyx. Medical Murray will continue to operate separately through its two facilities in the Chicagoland area.

This transaction enables Design & Development center support and advanced manufacturing for customers and bolsters expertise in catheter-based interventional products and transcatheter solutions, including implantable stents and frames, complex catheters, and delivery systems. 

Aptyx has been known for producing engineered products in molding, extrusion, coating solutions, and medical device assembly. By combining with Medical Murray, Aptyx will now be able to provide a complete manufacturing solution for catheter-based interventional and implantable products.

“We’re committed to conquering technical challenges and delivering on time and cost-efficient products for the structural heart, vascular, neurovascular, and other key end markets,” noted Leopold. “Joining Aptyx and combining our comprehensive experience in interventional markets provides the rocket fuel for long-term growth.”